Conclusion: miRNA 1260, 21, 940 and LET-7B have the potential to beused as a novel biomarkers in identifying patients with CIN 1 whowill progress to CIN 3 within 2 years. TGF-Β1 plays a multifunctionalrole in tumorpathogenesis actingeither as a tumorgrowth inhibitororasan enhancer of tumor progression via immune cell suppression. TGF-Β1has been found to be overexpressed in CIN 1 compared to CIN 3.

doi:10.1016/j.ygyno.2012.01.044

21Survivorship Care: Who Do Gynecologic Cancer Patients Prefer?M. Schlumbrecht, Charlotte C. Sun, M. Huang, A. Milbourne, D. Bodurka.The University of Texas, MD Anderson Cancer Center, Houston, TX.

Objectives: With health care reform imminent, appropriate triagingof patients who have entered post-treatment surveillance is crucial.Input from patients regarding their desires for survivorship care is anecessary part of this task. The objective of this study was to assessthe preferences of patients for surveillance and survivorship careafter the completion of treatment.Methods: A 38-item survey was developed and launched inconjunction with the Foundation for Women's Cancer (FWC). Anemail with a link to the survey was sent to all women registered asgynecologic cancer survivors with the FWC, and the survey wasannounced on the organization's website. Only respondents whowere without evidence of recurrent disease were included in theanalysis. Patients were asked whether they would prefer to see their

benign gynecologist or oncologist for a number of symptoms anddiagnoses, and when they felt comfortable transferring their care outof their oncologists' officies. Analyses were performed with summarystatistics and chi-square.Results: 605 patients completed the questionnaire. Of these, 436 hadnot recurred, and were included in the analysis. 366 (84%) had aprimary ovarian malignancy, 285 (65%) were older than 50 years ofage, and 372 (85%)were primarily treated by a gynecologic oncologist.54% of the respondents (n=236) reported not being willing to see aphysician other than their primary oncologist for survivorship care atany time, and 28% (n=120) reported being willing to see a benigngynecologist for surveillance and survivorship care five years aftercompletion of treatment. A significantly greater number of women ageb60 years were willing to see a benign gynecologist for surveillanceand survivorship care at one year post-treatment compared tothoseN=60 years (28 vs. 1, p=0.008). With the exception ofcounseling for fertility, sexual dysfunction, andmenopause symptoms,respondents preferred management by their oncologist rather thantheir benign gynecologist for conditions which were both cancer-related (fistula, bowel obstruction, recurrence surveillance) and notcancer-related (diabetes, hypertension, hypothyroidism).Conclusion: Gynecologic cancer survivors prefer that their oncolo-gists provide the majority of their survivorship care. Reconcilingpatient needs with physician and financial constraints will be achallenge as the survivor population continues to grow.

doi:10.1016/j.ygyno.2012.01.045

Abstracts S197